Intellia Therapeutics (NTLA) Metrics: History & Chart

Intellia Therapeutics, Inc.(NTLA)

Biotechnology · Cambridge, MA

$12.29+0.17 (+1.36%)

Delayed quote: Oct 2, 2026, 3:55 PM EDT

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Cambridge, MA

377 employees

www.intelliatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Leonard

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.33%
30D Total Return	-4.49%
YTD Total Return	+34.82%
1Y Total Return	-35.39%
3Y Total Return	-61.67%
5Y Total Return	-90.96%
10Y Total Return	-28.81%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+34.82%
2025	-22.90%
2024	-61.76%
2023	-12.61%
2022	-70.49%
2021	+117.35%
2020

CAGR TTM	-35.41%
CAGR 3Y	-27.31%
CAGR 5Y	-38.17%
CAGR 10Y	-3.34%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

NTLA Valuation Metrics

NTLA Stock Price Metrics

NTLA Dividend Metrics

NTLA Growth Rate Metrics

NTLA Discounted Cash Flow Metrics

NTLA Returns By Period

NTLA Yearly Returns

NTLA Average Annual Returns By Period (CAGR)

NTLA Revenue Metrics

NTLA PE Ratio Metrics

NTLA PS Ratio Metrics

NTLA PB Ratio Metrics

NTLA Price to Free Cash Flow Ratio Metrics

NTLA Debt to Equity Ratio Metrics

NTLA PEG Ratio Metrics

NTLA FCF Yield

NTLA Earnings Yield

NTLA EBITDA Yield

NTLA OCF Yield

NTLA EV/EBIT Ratio Metrics

NTLA EV/EBITDA Ratio Metrics

NTLA EV/Assets Ratio Metrics

NTLA EV/Sales Ratio Metrics

NTLA Current Ratio Metrics

NTLA Quick Ratio Metrics

NTLA ROIC Metrics

NTLA Return on Assets Metrics

NTLA Return on Equity Metrics

NTLA Net Profit Margin Metrics

NTLA Gross Profit Margin Metrics

NTLA Tax Rate Metrics

PS Ratio	27.19
PS Ratio Avg TTM	23.21
PS Ratio Avg 3Y	33.15
Current VS TTM Avg	+17.15%
Current VS 3Y Avg	-17.97%
Current VS 5Y Avg	-43.87%

PB Ratio	2.22
PB Ratio Avg TTM	2.09
PB Ratio Avg 3Y	1.93
Current VS TTM Avg	+6.35%
Current VS 3Y Avg	+14.94%
Current VS 5Y Avg	-15.34%

PFCF Ratio	22.54
PFCF Ratio Avg TTM	13.58
PFCF Ratio Avg 3Y	13.58
Current VS TTM Avg	+65.98%
Current VS 3Y Avg	+65.98%
Current VS 5Y Avg	+65.98%

Debt/Equity Ratio	0.10
Debt/Equity Ratio Avg TTM	0.13
Debt/Equity Ratio Avg 3Y	0.12
Current VS TTM Avg	-21.66%
Current VS 3Y Avg	-16.71%
Current VS 5Y Avg	-9.13%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	4.44%
FCF Yield Avg TTM	7.92%
FCF Yield Avg 3Y	7.92%
Current VS TTM Avg	-43.94%
Current VS 3Y Avg	-43.94%
Current VS 5Y Avg	-43.94%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.85
Ev/Assets Ratio Avg TTM	1.66
Ev/Assets Ratio Avg 3Y	1.53
Current VS TTM Avg	+11.73%
Current VS 3Y Avg	+20.87%
Current VS 5Y Avg	-9.15%

Ev/Sales Ratio	26.64
Ev/Sales Ratio Avg TTM	22.14
Ev/Sales Ratio Avg 3Y	32.41
Current VS TTM Avg	+20.34%
Current VS 3Y Avg	-17.80%
Current VS 5Y Avg	-43.24%

Current Ratio	6.65
Current Ratio Avg TTM	5.85
Current Ratio Avg 3Y	6.97
Current VS TTM Avg	+13.72%
Current VS 3Y Avg	-4.66%
Current VS 5Y Avg	-8.27%

Quick Ratio	6.65
Quick Ratio Avg TTM	5.85
Quick Ratio Avg 3Y	6.97
Current VS TTM Avg	+13.72%
Current VS 3Y Avg	-4.66%
Current VS 5Y Avg	-8.27%

ROIC	(54.45%)
ROIC Avg 3Y	(51.91%)
ROIC Avg 5Y	(44.37%)
Current VS 3Y Avg	-4.88%
Current VS 5Y Avg	-22.73%
Current VS 10Y Avg	-56.39%

ROA	(46.66%)
ROA Avg TTM	(11.74%)
ROA Avg 3Y	(10.99%)
Current VS TTM Avg	-297.36%
Current VS 3Y Avg	-324.50%
Current VS 5Y Avg	-363.90%

ROE	(54.96%)
ROE Avg TTM	(61.34%)
ROE Avg 3Y	(55.28%)
Current VS TTM Avg	+10.40%
Current VS 3Y Avg	+0.57%
Current VS 5Y Avg	-13.75%

Net Profit Margin	(672.16%)
Net Profit Margin Avg TTM	(778.78%)
Net Profit Margin Avg 3Y	(852.06%)
Current VS TTM Avg	+13.69%
Current VS 3Y Avg	+21.11%
Current VS 5Y Avg	+22.97%

Gross Profit Margin	76.47%
Gross Pft Margin Avg TTM	(135.79%)
Gross Pft Margin Avg 3Y	(213.04%)
Current VS TTM Avg	+156.31%
Current VS 3Y Avg	+135.89%
Current VS 5Y Avg	+119.29%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	-100.00%